Intervention not reported
Adverse events (AEs) (grade 3 or 4) ‐ Network included 19 pairwise comparisons ‐ Mean risk with SUN across trials3 in this network: 70.6% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
1 finding from 1 review
Intracranial hemorrhage on imaging at 24 hours · people with acute ischemic stroke
Thrombo‐aspiration alone showed no clear difference in intracranial hemorrhage on imaging at 24 hours compared with stent‐retrieval thrombectomy alone (high certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage at · people with acute ischemic stroke
Thrombo‐aspiration alone showed no clear difference in symptomatic intracranial hemorrhage at 24 hours compared with stent‐retrieval thrombectomy alone (high certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes symptomatic intracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Major extracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes major extracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Pain intensity (mean across treatment or at end of treatment; length of treatment varied across trials; various pain intensity scales; SMD) · adults with cancer‐related pain
It is very uncertain whether CR oxycodone changes pain intensity (mean across treatment or at end of treatment; length… compared with IR oxycodone (very low certainty).
1 finding from 1 review
Constipation · adults with cancer‐related pain
It is very uncertain whether CR oxycodone changes constipation ‐ only English language studies (Event rate during… compared with CR morphine (very low certainty).
2 findings from 1 review
Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · adults with cancer‐related pain
CR oxycodone showed no clear difference in drowsiness/somnolence (Event rate during treatment, length of… compared with CR morphine (low certainty).
1 finding from 1 review
Nausea · adults with cancer‐related pain
CR oxycodone showed no clear difference in nausea (Event rate during treatment, length of treatment varied… compared with CR morphine (low certainty).
1 finding from 1 review
Vomiting · adults with cancer‐related pain
It is very uncertain whether CR oxycodone changes vomiting (Event rate during treatment, length of treatment varied… compared with CR morphine (very low certainty).
1 finding from 1 review
Constipation · adults with cancer‐related pain
It is very uncertain whether CR oxycodone changes constipation (Event rate during treatment, length of treatment… compared with IR oxycodone (very low certainty).
1 finding from 1 review
Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · adults with cancer‐related pain
It is very uncertain whether CR oxycodone changes drowsiness/somnolence (Event rate during treatment, length of… compared with IR oxycodone (very low certainty).
1 finding from 1 review
Nausea · adults with cancer‐related pain
It is very uncertain whether CR oxycodone changes nausea (Event rate during treatment, length of treatment varied… compared with IR oxycodone (very low certainty).
1 finding from 1 review
Vomiting · adults with cancer‐related pain
It is very uncertain whether CR oxycodone changes vomiting (Event rate during treatment, length of treatment varied… compared with IR oxycodone (very low certainty).
1 finding from 1 review
Participant adherence to intervention · 5‐ to 8‐year‐old children with amblyopia
1 finding from 1 review
Proportion of participants experiencing an adverse event of permanent diplopia (double vision) Reports of diplopia across all measured time points · 5‐ to 8‐year‐old children with amblyopia
1 finding from 1 review
Major bleeding (intracranial and extracranial) · people with cerebral small vessel disease and no dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found